MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer
- PMID: 26202377
- PMCID: PMC6496401
- DOI: 10.1111/cpr.12202
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer
Abstract
Colorectal cancer (CRC) is the fourth leading cause of cancer-related death globally. Chemotherapy regimens consisting of 5-fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan are the first-line options for treatment of metastatic CRC. However, primary or acquired resistance to these chemotherapeutics is a major clinical challenge. MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate gene expression post-transcriptionally. miRNAs play important roles in many cancer-related processes, including cell proliferation, apoptosis and invasion, and their dysregulation is implicated in colorectal tumourigenesis. Pertinent to chemotherapy, increasing evidence has revealed that miRNAs can be directly linked to chemosensitivity in CRC. In this review, we summarize current evidence concerning the role of miRNAs in prediction and modulation of cellular responses to 5-FU, oxaliplatin and irinotecan in CRC. We also discuss the possible targets and intracellular pathways involved in these processes.
© 2015 John Wiley & Sons Ltd.
Figures
Similar articles
-
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.Mol Oncol. 2014 Feb;8(1):59-67. doi: 10.1016/j.molonc.2013.09.001. Epub 2013 Sep 21. Mol Oncol. 2014. PMID: 24119443 Free PMC article. Clinical Trial.
-
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.Braz J Med Biol Res. 2001 Sep;34(9):1087-103. doi: 10.1590/s0100-879x2001000900001. Braz J Med Biol Res. 2001. PMID: 11514832 Review.
-
FDA drug approval summaries: oxaliplatin.Oncologist. 2004;9(1):8-12. doi: 10.1634/theoncologist.9-1-8. Oncologist. 2004. PMID: 14755010 Clinical Trial.
-
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.World J Gastroenterol. 2014 Sep 7;20(33):11727-35. doi: 10.3748/wjg.v20.i33.11727. World J Gastroenterol. 2014. PMID: 25206276 Free PMC article. Review.
-
Role of genomic markers in colorectal cancer treatment.J Clin Oncol. 2005 Jul 10;23(20):4545-52. doi: 10.1200/JCO.2005.19.752. J Clin Oncol. 2005. PMID: 16002846 Review.
Cited by
-
MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression.Oncol Lett. 2017 Feb;13(2):722-730. doi: 10.3892/ol.2016.5463. Epub 2016 Dec 6. Oncol Lett. 2017. PMID: 28356951 Free PMC article.
-
BANCR: a cancer-related long non-coding RNA.Am J Cancer Res. 2017 Sep 1;7(9):1779-1787. eCollection 2017. Am J Cancer Res. 2017. PMID: 28979803 Free PMC article. Review.
-
CCAT1: a pivotal oncogenic long non-coding RNA in human cancers.Cell Prolif. 2016 Jun;49(3):255-60. doi: 10.1111/cpr.12252. Epub 2016 May 1. Cell Prolif. 2016. PMID: 27134049 Free PMC article. Review.
-
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer.Front Oncol. 2021 May 4;11:638537. doi: 10.3389/fonc.2021.638537. eCollection 2021. Front Oncol. 2021. PMID: 34017681 Free PMC article.
-
miR‑383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24‑mediated NF‑κB signaling pathway.Int J Oncol. 2021 Nov;59(5):87. doi: 10.3892/ijo.2021.5267. Epub 2021 Sep 24. Int J Oncol. 2021. PMID: 34558639 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69–90. - PubMed
-
- Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal C (2005) Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 6, 871–876. - PubMed
-
- Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first‐line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20, 1842–1847. - PubMed
-
- Temraz S, Mukherji D, Alameddine R, Shamseddine A (2014) Methods of overcoming treatment resistance in colorectal cancer. Crit. Rev. Oncol. Hematol. 89, 217–230. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical